Mahamaya Lifesciences Limited has filed its quarterly compliance certificate with the Bombay Stock Exchange for the quarter ended March 31, 2026, fulfilling its obligations under SEBI (Depositories and Participants) Regulations, 2018. The submission demonstrates the company's commitment to maintaining regulatory compliance and transparency with market authorities.

Regulatory Compliance Details

The certificate was submitted pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, dated April 4, 2026. Company Secretary and Compliance Officer Shilpi Bhardwaj signed the submission on behalf of Mahamaya Lifesciences Limited, ensuring proper authorization and accountability for the regulatory filing.

Share Dematerialization Status

KFin Technologies Limited, serving as the company's Registrar and Share Transfer Agent, confirmed that Regulation 74(5) is not applicable to Mahamaya Lifesciences Limited. This determination stems from the fact that the entire shareholding of the company remains in dematerialized form, with no physical share certificates outstanding.

The registrar's certificate, dated April 2, 2026, and signed by Senior Manager S Balaji Reddy, specifically states that no requests for rematerialization were received from any company members during the quarter ended March 31, 2026. This indicates complete digital holding of shares among all shareholders.

Corporate Information

Mahamaya Lifesciences Limited, formerly known as Mahamaya Lifesciences Pvt. Ltd., operates from its registered office located at Tower B-3, Spaze ITech Park, Sector-49, Sohna Road, Gurugram. The company holds ISO 9001:2015 certification and maintains its corporate identification number as U24233DL2002PLC115261.

Registrar Operations

KFin Technologies Limited operates from multiple locations to serve its clients effectively. The operations center is situated at Selenium Tower B, Financial District, Nanakramguda, Hyderabad, while the registered office is located at The Centrium, Thane West. This infrastructure enables comprehensive registrar and share transfer services for listed companies.

The quarterly compliance certificate filing reflects standard corporate governance practices and regulatory adherence requirements for publicly listed companies in India. Such submissions ensure transparency and maintain investor confidence in the company's operational compliance framework.

Mahamaya Lifesciences Limited has submitted its mandatory annual disclosure to BSE Limited, confirming compliance with SEBI regulations regarding promoter shareholdings for the financial year ended 31st March 2026. The pharmaceutical company filed the disclosure under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 on 3rd April 2026.

Regulatory Compliance Declaration

The disclosure was formally submitted by Company Secretary and Compliance Officer Shilpi Bharadwaj to BSE Limited's listing department. The filing confirms that no encumbrance has been created on shares held by the promoter and promoter group during the financial year ended 31st March 2026.

Promoter Group Confirmation

Managing Director Krishnamurthy Ganesan, acting on behalf of the promoter and promoter group, provided a separate declaration dated 2nd April 2026. The declaration specifically states that members of the promoter and promoter group, along with persons acting in concert, have not made any encumbrance of shares, directly or indirectly, during the financial year ended 31st March 2026.

Company Information

Mahamaya Lifesciences Limited, formerly known as Mahamaya Lifesciences Pvt. Ltd., operates from its registered office in Gurugram, Haryana. The company maintains its corporate headquarters at Spaze ITech Park, Sector-49, Sohna Road, and holds ISO 9001:2015 certification for quality management systems.

SEBI Compliance Framework

The disclosure under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 is a mandatory annual requirement for listed companies. This regulation ensures transparency in promoter shareholding patterns and prevents unauthorized encumbrance of shares that could affect minority shareholders' interests. The timely filing demonstrates the company's commitment to maintaining regulatory compliance and corporate governance standards.